| Literature DB >> 32678061 |
Derek M Griffith1, Garima Sharma2, Christopher S Holliday3, Okechuku K Enyia4, Matthew Valliere5, Andrea R Semlow6, Elizabeth C Stewart6,7, Roger Scott Blumenthal2.
Abstract
Data suggest that more men than women are dying of coronavirus disease 2019 (COVID-19) worldwide, but it is unclear why. A biopsychosocial approach is critical for understanding the disproportionate death rate among men. Biological, psychological, behavioral, and social factors may put men at disproportionate risk of death. We propose a stepwise approach to clinical, public health, and policy interventions to reduce COVID-19-associated morbidity and mortality among men. We also review what health professionals and policy makers can do, and are doing, to address the unique COVID-19-associated needs of men.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32678061 PMCID: PMC7380297 DOI: 10.5888/pcd17.200247
Source DB: PubMed Journal: Prev Chronic Dis ISSN: 1545-1151 Impact factor: 2.830
Biopsychosocial Determinants and Associated Practice, Policy, and Clinical or Biomedical Intervention Strategies for Reducing Disproportionate COVID-19–Related Morbidity and Mortality Among Men
| Determinants (Risk Factors) | Type of Strategy | Strategies (Varying Levels) |
|---|---|---|
|
| ||
| Comorbidities such as hypertension, cardiovascular disease, chronic kidney disease, diabetes, and chronic obstructive pulmonary disease | Practice |
Educate men with comorbidities during routine visits, emergency encounters, and follow-up telephone calls about their susceptibility to COVID-19 and about when to obtain urgent care rather than stay at home for fear of contracting the virus. Reassure patients that new symptoms of myocardial infarction and stroke still need to urgently be addressed. |
| Policy |
Increase investment in primary prevention of chronic diseases. | |
| Use ACEIs or ARBs | Clinical or biomedical |
Physicians and medical researchers should consider consequences of withholding ACEIs or ARBs for men with hypertension. Clinicians should actively assess risks and optimize cardiovascular health. |
| Sex-dependent immune response and the presence of disease susceptibility genes | Clinical or biomedical |
Design clinical trials and population health databases; consider sex as a biological variable that might affect drug efficacy, treatment options, and adverse outcomes. Consider immunologic sex difference in mitigation of disease and clinical trials that consistently investigate sex differences. |
| ACE2 and TMPRSS2 | Clinical or biomedical |
Unravel which cellular factors are used by SARS-CoV-2; review for insights into viral transmission; and reveal therapeutic targets for vaccines and medical therapy. |
|
| ||
| Men who are at increased risk because of cardiometabolic or other preexisting risk factors or are at increased risk because they use tobacco, alcohol, or other drugs | Practice |
Focus on helping men who have underlying conditions that increase their risk of COVID-19 mortality to change behaviors that could make it more difficult for their bodies to fight COVID-19–related conditions. Promote American Heart Association’s Life’s Simple 7, including smoking cessation, maintaining a healthy weight, adequate physical activity and balanced healthy diet and target values for cholesterol, blood pressure, and blood glucose |
| Men who perceive reduced susceptibility and severity of disease and engage in higher-risk behaviors | Policy |
Pass risk-reduction policies. |
| Practice |
Encourage health professionals to educate men on how to reduce viral transmission. Engage men’s partners, families, and trusted loved ones about men’s unique biological or psychosocial risks. | |
| Clinical or biomedical |
Develop and institute COVID-19–specific clinical and operational guidelines in specialties; these include patient education information on occupational risk mitigations, recognizing signs and symptoms of COVID-19 infection, hand hygiene, surface decontamination, and protecting family members. | |
| Men tend to delay seeking clinical care for COVID-19 symptoms | Practice |
Eliminate barriers associated with underutilization of health services and improving health literacy. Engage men’s partners and families to support and encourage symptomatic men to seek care. Engage community health workers to provide direct outreach to men with comorbidities to provide culturally and linguistically appropriate preventive care. |
| Policy |
Increase access to community-wide testing; eliminate costs of testing and other barriers. Collect data related to COVID-19, including data on testing, hospitalizations, intensive care unit admissions, and fatalities, disaggregated by race, ethnicity, sex, and gender at the local and national level to help distribution of resources. | |
Abbreviations: ACE2, angiotensin-converting enzyme 2; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TMPRSS2, transmembrane protease, serine 2.
FigureIntervention strategies to reduce men’s COVID-19 mortality risk.